CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy announces the successful completion of its previously announced acquisition of Naveris, following the satisfaction of all closing conditions. Naveris’s lead product, NavDx, is a blood-based test that detects and monitors viral-mediated cancers — including human papillomavirus (HPV)-associated head and neck and anal cancers — from diagnosis through post-treatment molecular residual disease (MRD) surveillance. NavDx is the first and only Medicare-covered assay for HPV-driven head and neck and anal cancer MRD.
Read the full article: CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology //
Source: https://www.businesswire.com/news/home/20260701539330/en/CareDx-Completes-Acquisition-of-Naveris-Extending-Leadership-into-High-Growth-Specialty-Oncology